|
 |
LovenoxThis page contains recent news articles, when available, and an overview of Lovenox but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Lovenox (when available) Enoxaparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Enoxaparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Enoxaparin is a well known and commonly used anticoagulant which has antithrombotic properties. Enoxaparin is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin. Enoxaparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Enoxaparin acts at multiple sites in the normal coagulation system. Small amounts of Enoxaparin in combination with antithrombin III (Enoxaparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of Enoxaparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Enoxaparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism Mechanism Of Action: The mechanism of action of Enoxaparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of Enoxaparin is well correlated to the inhibition of factor Xa. Enoxaparin interacts with Antithrombin III, Prothrombin and Factor X. News Articles on Enoxaparin Blood thinners - Dec 28, 2009 Lovenox, also called enoxaparin, is a form of heparin called fractionated heparin. Lovenox does not require monitoring of its blood levels and it can be ... Augusta Free Press Wrong Blood Thinners for Dialysis Patients Often Given: Study - Dec 11, 2009 Those dialysis patients given Lovenox or Integrilin had a 66% increased chance of in-hospital bleeding and potentially an increased risk of death as well. ... AboutLawsuits.com Carmen McArthur's Blood Clotting Story - Dec 11, 2009 I was admitted to the hospital and given Lovenox shots and Coumadin® pills. The gravity of my condition didn't become real until I woke up in the ICU with a ... National Alliance for Thrombosis and Thrombophilia (press release) Piper Jaffray Initiates Coverage on Watson Pharmaceuticals (WPI) with an ... - Dec 10, 2009 Concerta and Lovenox are key US generics opportunities for Watson; we view these as high-risk with little visibility to launch. ... StreetInsider.com (subscription) Sanofi-Aventis, eyeing OTC market, beefs up US presence - Dec 23, 2009 ...as many of its prescription drugs come off patent, including cancer drug Eloxatin, heart drug Plavix and anti-clotting product Lovenox. ... Medical Marketing and Media Sanofi-aventis launches new production unit at Le Trait site, to double ... - Dec 11, 2009 The state-of-the-art production lines will include new filling, inspection and packaging systems (part of the @live project – Lovenox Injectable Vaccines ... pharmabiz.com Sanofi-Aventis Reaches over the Counter - Dec 24, 2009 Sanofi's Lovenox, Plavix, Ambien CR and Eloxatine are all facing or potentially face generic competition. Building over-the-counter and consumer product ... Seeking Alpha (blog) Sanofi boosts syringe production capacity in France - Dec 16, 2009 Key products made at the plant include low molecular weight heparin Lovenox (enoxaparin), which has seen 14% growth worldwide in the first nine months of ... Pharmafocus Misuse Of Blood Thinners In Dialysis Patients Reported - Dec 10, 2009 Reuters/ABC News reports on research published in the Journal of the American Medical Association that examined the misuse of two blood thinners - Lovenox ... Medical News Today (press release) High Flyers: NBIX, HNSN, MNTA - Dec 22, 2009 ...'Watch Closely' stock for me; and I'm leaning close toward a 'Buy' as it awaits marketing approval for its version of the anti-clotting drug Lovenox. ... Small Cap Network Senate to review rules for prescription drug plan managers - Dec 11, 2009 Alyeska employee Ric Weinrick said the incident occurred when he tried to fill his wife's prescription for Lovenox, an anticoagulant, at his local Fred ... Alaskajournal.com Ready to rumble: Pfizer's generic biotech drug push could pit it against Amgen - Dec 11, 2009 ...told Bloomberg that Pfizer may sell its first copies of medicines like Amgen's anemia therapy Epogen, or Sanofi-Aventis's (SNY) blood thinner Lovenox, ... Daily Finance (blog) Sanofi-Aventis Names New Chairman - Dec 16, 2009 ...and directed a private investment fund. Sanofi-Aventis is best known for making blood thinners Lovenox and Plavix, and the diabetes treatment Lantus. Manufacturing.net SANOFI-AVENTIS : soutenu par Oddo - Jan 4, 2010 Pour sa part, le courtier a pris l'option d'une baisse régulière du chiffre d'affaires de Lovenox aux Etats-Unis à partir de 2011. Toutefois, il pense qu'en ... Zonebourse.com Sanofi-aventis double sa capacité de production de seringues et diversifie sa ... - Dec 11, 2009 Les nouvelles unités de remplissage, d'inspection et de conditionnement (dans le cadre du projet @live - Lovenox Injectables Vaccins Extension) permettent ... Edubourse.com (Communiqué de presse) Sanofi-aventis : Jefferies toujours prudent - Dec 21, 2009 Prudent sur le court terme notamment en raison de la menace des génériques de Lovenox aux Etats-Unis, le broker demeure neutre sur le dossier avec un ... Trading Sat DrakkarOnline - le Portail Normand de l'Information Economique (http://www ... - Dec 14, 2009 Les nouvelles unités de production doivent permettre de répondre à un marché en croissance au plan mondial du Lovenox (+13% en 2008) et développer le ... Drakkaronline.com วิจัยพบหมà¸à¸¡à¸°à¸?ันมัà¸?ง่าย จ่ายยาไม่ดูฉลาà¸? - Dec 11, 2009 100000 ราย ซึ่งยาที่ใช้เป็นยาละลายลิ่มเลืà¸à¸”มี 2 ประเภท คืภ“เลิฟน็à¸à¸?ซ์â€? (Lovenox) หรืà¸à¸—ี่รู้จัà¸?à¸?ันดีว่า “enoxaparinâ€? ผลิตโดยบริษัท ซาโนฟิ-à¸à¹€à¸§à¸™à¸•à¸´à¸ª เà¸à¸ªà¹€à¸ ... ไทยรัฐ í™”ì?´ìž?, ë°”ì?´ì˜¤ì‹œë°€ëŸ¬ 시장 본격 진출 - Dec 9, 2009 ...나 ì?¸ìˆ˜ë?„ ê³ ë ¤í•˜ê³ ìžˆìœ¼ë©° 첫 번째 ë°”ì?´ì˜¤ì‹œë°€ëŸ¬ ì œí’ˆì?€ ì•”ì ì?˜ 빈혈약 'ì—?í?¬ê²?'(Epogen)ì?´ë‚˜ 사노피ì?˜ í˜ˆì „ì œê±°ì œ 'ë¡œë² ë…¹ìŠ¤'(Lovenox) 등ì?´ ë? 것으로 ë³´ì?¸ë‹¤. ... 헬스코리아뉴스 «Pfizer» приÑ?матриваетÑ?Ñ? к рынку биогенериков - Dec 10, 2009 «Amgen Inc.») или Clexane ® /Lovenox ® /КлекÑ?ан ® (Ñ?нокÑ?апарин, «sanofi-aventis»), количеÑ?тво которых в конечном Ñ?чете Ñ?оÑ?тавит 10–15 наименований. ... Аптека online Pfizer quer entrar no mercado de genéricos biotecnológicos - Dec 10, 2009 Segundo a Bloomberg, a empresa poderá comercializar dentro de cinco anos as primeiras cópias de fármacos injectáveis como o Epogen® (Amgen) ou o Lovenox® ... RCM Pharma Sanofi-Aventis "hold" - Dec 21, 2009 Das Risiko von Lovenox-Generika nehme zu. Der kurzfristige Ausblick werde durch Kostensenkungen verbessert, doch die mittelfristigen Wachstumsperspektiven ... newratings.de Sanofi-Aventis "buy" - Dec 10, 2009 Die beiden größten Präparate Lantus (weltweit führend bei Insulin, Umsatz +21,7%) und Lovenox (+13,7%) hätten in allen drei Regionen gut abgeschnitten. ... newratings.de San Jose Sharks' Jed Ortmeyer battles blood-clotting disorder - Nov 9, 2009 The blood thinner, Lovenox, needs to be in his system during the down time when he's not on the ice. And it needs to be out of his system when he plays or ... San Jose Mercury News Sanofi 3Q Pft +6.8%; Ups Target On Swine Flu Vaccine - Oct 30, 2009 Double-digit sales growth of diabetes drug Lantus and blood thinner Lovenox helped offset a steep drop in sales of cancer treatment Eloxatin, which were hit ... Wall Street Journal Senators Probe Drug Firm's Hiring of Kroll - Nov 1, 2009 The only version of the drug available is Sanofi-Aventis SA's Lovenox, which lost patent protection about a year ago; it had global sales of $3.5 billion in ... Wall Street Journal Global Cardiovascular Drugs Market By Bharatbook.com - Nov 5, 2009 The years 2011 to 2015 will mark a period of high volatility in the cardiovascular market as key products - including blockbusters Plavix and Lovenox - face ... PRMinds (press release) Warfarin given at therapeutic INR during pulmonary vein isolation yielded no ... - Nov 2, 2009 No heparin or enoxaparin (Lovenox, Sanofi-Aventis) was administered before the ablation procedures. Patients were treated with uninterrupted warfarin ... Cardiology Today Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards - Oct 21, 2009 In My Skin -- Company: DraftFCB Healthcare -- Pharmaceutical -- Lovenox - Lovenox Virtual Convention Booth -- Company: Euro RSCG Life Catapult Poster: ... Reuters ADR REPORT: ADRs Fall As US Stocks, French Shares Tumble - Oct 30, 2009 FR) on Friday reported a 6.8% rise in third-quarter net profit due to robust sales growth of blockbuster drugs Lantus and Lovenox, and raised full-year ... Wall Street Journal Nielsen Announces Finalists for the First-Ever CLIO Healthcare Awards - Oct 21, 2009 Lovenox - Lovenox Virtual Convention Booth -- Company: Euro RSCG Life Catapult -- Devices & Diagnostics -- Vibe hearing aids - Why hide your Vibe? ... SmartBrief Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009 - Oct 30, 2009 Third-quarter net sales of Lovenox®, the leading low molecular weight heparin on the market, rose by 13.7% to euro 747 million, driven by strong growth in ... Reuters Forecast Insight - Antithrombotics - Market growth dependent on new agents ... - Oct 26, 2009 The growth can be mainly attributed to the increased uptake of Plavix (clopidogrel) and Lovenox (enoxaparin) in all of the seven major markets. ... PR-Inside.com (Pressemitteilung) Momenta Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript - Nov 6, 2009 The strategy is similar to what we've perused with heparin starting with the development of a generic Lovenox continuing with M118 and then finally M402, ... Seeking Alpha (blog) Shrugging Off the Side Effects - Oct 31, 2009 Of those three, the one to worry about is Lovenox. The drug lost patent protection in the US a while ago, after Teva Pharmaceutical (Nasdaq: TEVA) and ... The Money Times Knights lineman returns for the love of the game - Oct 21, 2009 He began giving himself shots of the drug Lovenox in his stomach, still unsure whether or not his athletic career was over. Hartlep's blood work improved ... Journal and Courier Pre-Market Stock Upgrades/Downgrades Oct 30, 2009 - Oct 30, 2009 ...drugs Lantus and Lovenox, and raised full-year guidance, citing an expected $500 million boost to fourth-quarter sales from the swine-flu vaccine. ... Wall Street Pit (blog) Unilife: Medical Device Innovator Creating Jobs in Pennsylvania - Oct 30, 2009 ...which is the largest buyer of pre-filled syringes in the world for injectable products such as the blood thinner Lovenox and influenza vaccines such as ... Seeking Alpha (blog) Sanofi-Aventis boekt winstgroei 6,8%; verhoogt outlook - Oct 30, 2009 Sanofi-Aventis zag dankzij een dubbelcijferige omzetgroei van diabetesmedicijn Lantus en bloedverdunner Lovenox de omzet met 8% klimmen tot euro 7,4 mrd. ... Financieele Dagblad Sanofi-Aventis en forme - Oct 30, 2009 Le chiffre d'affaires progresse de 8% à 7,4 milliards d'euros, grâce à la bonne performances des médicaments vedettes du groupe, le Lovenox (+13,7%), ... La Tribune.fr HIGHLIGHTS CORPORATE - Oct 30, 2009 La societa' francese Sanofi-Aventis ha riportato una crescita degli utili del 6,8% nel terzo trimestre, trainata dalle vendite dei farmaci Lantus e Lovenox ... Borsa Italiana Sanofi-aventis : Jefferies prudent sur le potentiel du Multaq - Nov 10, 2009 Il juge en effet le titre pleinement valorisé au regard du risque générique concernant le Lovenox, et des risques sur la sécurité du Lantus et la politique ... Trading Sat 赛诺è?²-安万特第三å£åº¦å‡€åˆ©æ¶¦å¢žé•¿6% - Oct 30, 2009 ...市场对赛诺è?²-安万特畅销è?¯å“?æŠ—è¡€æ “è?¯ä¾?诺è‚?ç´ (Lovenox)以å?Šç³–尿病治疗è?¯Lantus的强劲需求为该公å?¸ç¬¬ä¸‰å£åº¦æ•´ä½“è?¯å“?é”€å”®å¥ å®šäº†ç¨³å›ºçš„åŸºç¡€ã€‚ 赛诺è?²-安万特今年å‰?9个月 ... 新浪网 Schweinegrippe-Boom bei Sanofi - Oct 30, 2009 Stark gefragt waren andererseits das Diabetes-Mittel Lantus mit einem Plus von fast 22 Prozent und das Antithrombose-Mittel Lovenox mit einem Plus von ... ARD Прибыль «sanofi-aventis» в III кв. возроÑ?ла на 16% - Nov 2, 2009 СШÐ?), в то времÑ? как доход от продаж Lovenox выроÑ? на 14% и доÑ?тиг 747 млн евро (1,1 млрд дол.). Объем продаж вакцин выроÑ? на 4,8%, Ñ?оÑ?тавив 1 млрд евро (1 ... Аптека online Sanofi-Aventis anticipe une hausse de 11 % de son BPA 2009 grâce au vaccin H1N1 - Nov 1, 2009 ...+14% pour Lovenox, +4% pour Plavix, «nous n'anticipons pas d'inflexion de tendance sur la fin de l'année, poursuit Jérôme Contamine. ... L'AGEFI Euronext en Europa: beurzen overwegend lager - Oct 30, 2009 ...van 2009 de nettowinst met 6,8% zien stijgen tot euro 1,42 mrd, geholpen door een robuste omzetgroei van de belangrijke medicijnen Lantus en Lovenox. ... Financieele Dagblad Sanofi-Aventis prend le contrôle d'un fabricant russe d'insuline - Oct 25, 2009 Le groupe est très présent dans le traitement du diabète avec son insuline Lantus, troisième produit de l'entreprise après le Lovenox et le Plavix. ... Les Échos ФранцузÑ?каÑ? компаниÑ? купила роÑ?Ñ?ийÑ?кого производителÑ? инÑ?улина - Oct 26, 2009 ИнÑ?улин Lantus Ñ?влÑ?етÑ?Ñ? третьим по важноÑ?ти продуктом предприÑ?тиÑ? поÑ?ле препаратов Lovenox и Plavix. Sanofi-Aventis уже говорила в Ñ?том году и о других ... inoСМИ.Ru 로슈 등 3분기 실ì ? 'ì‹ ì¢…í”Œë£¨ 특수' - Nov 1, 2009 ...그밖ì—?ë?„ 사노피 ì œí’ˆ 중 ì?¸ìŠ?린 '란투스'ì?˜ 3분기 매출ì?´ 22% ì¦?가한 12억달러, 'ë¡œë² ë¡?스'(Lovenox, enoxaparin)ì?˜ 매출ì?´ 14% ì¦?가한 11억달러를 기ë¡?, 미êµÂ·ìœ 럽ì?˜ ... 디지틀보사 US rejects Momenta copy of Sanofi's drug Lovenox - Nov 6, 2007 By Lewis Krauskopf and Ben Hirschler. NEW YORK/LONDON, Nov 6 (Reuters) - US regulators have rejected Momenta Pharmaceuticals Inc's (MNTA. ... Reuters Biotech, pharma stocks dip; Sanofi falls on Lovenox ruling - MarketWat... - Feb 9, 2007 By Val Brickates Kennedy, MarketWatch. BOSTON (MarketWatch) -- Biotech and pharmaceutical stocks closed lower Friday as shares of Sanofi-Aventis slipped on ... MarketWatch J&J blood clot drug beats Sanofi-Aventis' Lovenox - May 30, 2008 NEW YORK --Johnson & Johnson said Friday its experimental drug to treat blood clots after orthopedic surgery proved more effective in a late-stage trial ... Boston Globe Sanofi's Lovenox Secure for Now - Apr 10, 2006 A federal appeals court has given Sanofi-Aventis (SNY Quote) a temporary reprieve in a patent fight over its best-selling drug, the anticoagulant Lovenox. ... TheStreet.com - TheStreet.com (subscription) Sanofi says US court gives unfavourable Lovenox judgement; co to … - Jun 16, 2005 PARIS (AFX) -Sanofi-Aventis said the US judge conducting the trial over alleged infringement of the patent for its Lovenox drug found in favour of its ... Forbes Bayer launches Xarelto in EU, cost matches Lovenox - Oct 2, 2008 LONDON (Reuters) - Bayer AG (BAYG.DE) has launched its new anticoagulant pill Xarelto in Britain and Germany, pricing the product on a par with ... Reuters UK Sanofi-Aventis recalls 30 lots of Lovenox syringes on overdose risk - Feb 10, 2006 PARIS (AFX) - Sanofi-Aventis said it recalled 30 lots of syringes pre-filled with enoxaparin anti-thrombosis treatment and sold under the Lovenox and ... Forbes Glaxo's Arixtra safer, just as effective as Sanofi's Lovenox - study - Sep 5, 2005 LONDON (AFX) - GlaxoSmithKline PLC's anti-blood clot drug Arixtra is just as effective as Sanofi-Aventis SA's Lovenox, and significantly less likely to ... Forbes Bayer's blood-clot drug beats Lovenox in key study - Jul 8, 2007 By Ben Hirschler. LONDON (Reuters) - Bayer AG's (BAYG.DE) experimental pill rivaroxaban is significantly more effective than standard injections of Lovenox ... Reuters US court affirms against Sanofi in Lovenox case - May 15, 2008 By Kim Dixon. WASHINGTON, May 14 (Reuters) - A US federal court on Wednesday affirmed a ruling that Sanofi-Aventis SA (SASY.PA: Quote, Profile, Research) ... Reuters India Sanofi sues over Lovenox copy - Aug 10, 2006 Sanofi is seeking an injunction to prevent Sandoz bringing the copy to market. Such legal actions are common against generic drug manufacturers but it is ... Times Online Lovenox gets expanded use for STEMI - May 18, 2007 BRIDGEWATER, NJ, May 18 (UPI) -- French firm Sanofi-aventis said Friday it hs been cleared for US sales of Lovenox for the most serious form of heart attack ... United Press International Andrx, Amphastar in deal for generic version of Sanofi-Aventis' Loveno... - May 5, 2005 ...it has entered into a marketing rights agreement with Amphastar Pharmaceuticals for a generic version of Lovenox, a treatment for deep vein thrombosis. ... Forbes US court affirms against Aventis in Lovenox case - May 14, 2008 WASHINGTON, May 14 (Reuters) - A US federal court on Wednesday affirmed a ruling that Sanofi-Aventis SA (SASY.PA) intended to deceive the patent office in ... Reuters Sanofi to appeal Lovenox patent ruling - Feb 13, 2007 PARIS, Feb 13 (Reuters) - French drugmaker Sanofi-Aventis (SASY.PA) plans to appeal a decision by a US court to invalidate its patent on bloodthinner ... Reuters Sanofi says Clexane/Lovenox approved in Japan - Jan 28, 2008 PARIS, Jan 28 (Reuters) - Sanofi-Aventis (SASY.PA) said on Monday that its anticoagulant Clexane/Lovenox has been approved for marketing in Japan for the ... Reuters … FINDINGS CONFIRM CLEXANE/LOVENOX LONG-TERM CLINICAL … - Sep 3, 2007 ...sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients ... Free with registration - AsiaPulse News - AccessMyLibrary.com Sanofi's Patent Problems Are Still Potent - Sep 11, 2006 The US trial for Lovenox was originally set for October, but it's been postponed ... More than 60% of Lovenox sales came from the US The injectable Lovenox, ... TheStreet.com - TheStreet.com (subscription) Sanofi-Aventis gets US priority review for new Lovenox indication - Feb 7, 2007 PARIS (AFX) - Sanofi-Aventis SA said it has been granted a priority review by the US Food and Drug Administration for its request of a new indication for ... Forbes EU agency okays Sanofi's Lovenox despite impurity - Jun 5, 2008 By Ben Hirschler. LONDON, June 5 (Reuters) - Doctors in Europe can continue to use Sanofi-Aventis SA's (SASY.PA) heparin medicine Lovenox, ... Reuters Rivaroxaban better than Sanofi's Lovenox - study - Dec 8, 2007 FRANKFURT, Dec 8 (Reuters) - Experimental drug rivaroxaban works better than the standard treatment with enoxaparin to prevent blood clots in patients ... Reuters UK Sanofi Says Taking Lovenox for Longer Time Prevents More Clots - Jul 8, 2007 By Angela Cullen. July 8 (Bloomberg) -- Sanofi-Aventis SA, France's largest drugmaker, said taking its Lovenox blood thinner for five weeks prevents more ... Bloomberg The Boston Globe Boston Capital column. - Jul 19, 2005 Sanofi-Aventis counts Lovenox as its best-selling drug. ... But it will have to prove it can do more than copy Lovenox to push its stock price much higher ... Free with registration - Boston Globe - AccessMyLibrary.com Momenta sees longer US review for generic Lovenox - Jun 28, 2007 NEW YORK, June 28 (Reuters) - Momenta Pharmaceuticals Inc. (MNTA.O) said on Thursday a US review of its application to sell a generic version of ... Reuters Sanofi Profit Falls as Recalls Hinder Lovenox Sales - Jul 31, 2008 By Trista Kelley. July 31 (Bloomberg) -- Sanofi-Aventis SA, France's largest drugmaker, reported second-quarter earnings that missed analyst estimates as ... Bloomberg Studies: Arixtra, Lovenox Reduce Risk of Death or Repeat Heart Attack - Mar 15, 2006 ...'Arixtra has got a lot of ground to make up against other low molecular weight heparins. In addition to being the market leader, Lovenox is licensed for ... Daily News Central J&J/Bayer blood clot drug beats Lovenox in trials - Dec 10, 2007 NEW YORK, Dec 10 (Reuters) - Johnson & Johnson (JNJ.N) said on Monday a pill it is developing with Bayer AG BAYG.DE was far better able to prevent blood ... Reuters New drugs fuel Sanofi profit rise - Mar 2, 2005 Sanofi-Aventis already reported a 10 percent rise in 2004 pro forma sales to €25.42 billion as six of its drugs, including Plavix, Lovenox and Eloxatin, ... New York Times Rest of Sanofi's contaminated Lovenox recalled - Sep 23, 2008 PARIS, Sept 23 (Reuters) - French drugmaker Sanofi-Aventis (SASY.PA) has recalled remaining batches of contaminated blood thinner Lovenox, a heparin, ... Reuters Momenta stock climbs on Novartis investment - The Boston Globe - Jul 26, 2006 Momenta has developed a copy of Lovenox , a blood thinner made by ... Made from the intestinal lining of pigs, Lovenox is a complex mixture of sugars that ... Boston Globe Sanofi-Aventis makes precautionary recall of 11 batches of Lovenox in... - May 16, 2008 Lovenox is Sanofi-Aventis (nyse: SNY - news - people )' biggest selling drug, with sales last year of 2.6 billion euros. Forbes Lovenox (enoxaparin) Goes Unfractionated Heparin One Better for Safety - Sep 6, 2006 By Neil Osterweil, Senior Associate Editor, MedPage Today. PARIS, Sept. 6 -- Lovenox (enoxaparin) appears to be somewhat safer than unfractionated heparin ... MedPage Today Sanofi exec expects Lovenox to remain top seller - Aug 1, 2007 LONDON, Aug 1 (Reuters) - Sanofi-Aventis (SASY.PA) pharmaceuticals head Hanspeter Spek said on Wednesday he expected injectable anticoagulant Lovenox to ... Reuters New type of anti-clotting drug misses testing goal - Aug 26, 2008 French drugmaker Sanofi-Aventis sells it under the brand names Lovenox, which is widely used, and Clexane, a brand name used in Japan. ... San Diego Union - Tribune - San Diego Union Tribune Weight-Loss Treatment to Get Review - Jun 24, 2005 ...on Acomplia to reduce its reliance on its two top sellers, blood thinner Plavix and anti-stroke treatment Lovenox, which face patent challenges. ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Boehringer clot drug matches Lovenox in hip study - Jul 11, 2007 LONDON, July 11 (Reuters) - Boehringer Ingelheim's experimental once-a-day pill dabigatran is as effective as injections of Lovenox in preventing blood ... Reuters … (R) Significantly Reduced Major Bleeding Compared To Lovenox(R) In... - Apr 10, 2006 ARIXTRA was as effective as Lovenox(R) for the primary composite endpoint of preventing death, myocardial infarction, and refractory ischemia (5.8 percent ... Medical News Today - Medical News Today (press release) Arixtra(R) has comparable efficacy to Lovenox(R)/Clexane(R) with less... - Sep 6, 2005 GlaxoSmithKline plc announced headline results from the largest clinical trial ever conducted in patients with acute coronary syndromes (ACS), ... Medical News Today - Medical News Today (press release) Lovenox reduces cardio risks but can cause bleeding - Mar 14, 2006 Sanofi-Aventis' anti-blood clot drug Lovenox reduced the risk of repeat heart attacks and deaths among people who suffered a major heart attack in a new ... FierceBiotech Sweden Pulls Contaminated Sanofi Heparin Batches - Apr 24, 2008 Lovenox is a version of heparin, a drug that's linked to contamination and deaths ... Lovenox, also known as Clexane, is Paris-based Sanofi's biggest drug, ... Bloomberg … Showed Comparable Efficacy to Lovenox/Clexane With Significantly … - Sep 9, 2005 STOCKHOLM, SWEDEN -- September 9, 2005 -- GlaxoSmithKline plc announced headline results from the largest clinical trial ever conducted in patients with ... DG News Sanofi quarter in line with forecasts; R&D disappoints - Apr 30, 2008 Generic competition and negative currency impact were partially offset by strong sales growth from blood thinner Lovenox, anticlotting drug Plavix, ... MarketWatch … Publishes PREVAIL Study Results Showing Lovenox(R) Superiority... - Apr 20, 2007 BRIDGEWATER, NJ, April 20 /PRNewswire-FirstCall/ -- Sanofi-aventis announced the publication of the PREVAIL (Prevention of VTE after Acute Ischemic Stroke ... RedOrbit Small firm figures big in war of drug giants. - Aug 14, 2006 The drug is a copycat version of Lovenox, a blood-thinning injection with annual sales ... At the center of the legal fight is Momenta's version of Lovenox, ... Free with registration - Boston Globe - AccessMyLibrary.com Sanofi-Aventis Developing New Drugs - Sep 17, 2007 Sanofi-Aventis said tests on the potential successor of Lovenox showed the anti-clotting medicine may work better than the original. ... San Francisco Chronicle Sanofi best-sellers help lift net profit in 3Q - Oct 31, 2008 French pharmaceutical giant Sanofi-Aventis said Friday that higher sales of blood thinners Lovenox and Plavix and diabetes treament Lantus helped lift net ... FOXNews ACC: Lovenox Reduces Deaths and Reinfarction After Thrombolysis for … - Mar 15, 2006 By Neil Osterweil, Senior Associate Editor, MedPage Today. ATLANTA, March 15 - After fibrinolysis for ST-elevation myocardial infarction (STEMI), Lovenox ... MedPage Today Momenta Pharmaceuticals Announces Abbreviated New Drug … - Aug 30, 2005 Sanofi-Aventis reported worldwide Lovenox sales of $2.4 billion in 2004. ... Like other low molecular weight heparins, Lovenox consists of a heterogeneous ... RedOrbit New Study Shows Lovenox(R) (Enoxaparin Sodium Injection) Is More … - Dec 12, 2006 ORLANDO, Fla., Dec. 12 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the results of the PREVAIL (Prevention of VTE after Acute Ischemic ... $4.95 - PR Newswire - ECNext Plavix sales hike profit for Sanofi-Aventis - Feb 12, 2008 The group's key drugs charted strong performances, with blood-thinner drug Plavix, antithrombotic Lovenox, and diabetes treatment Lantus posting comparable ... Toronto Star Bayer Shares Rise After Anti-Clotting Drug Beats Rival in Test - Jul 9, 2007 Of the Lovenox patients, 19 percent experienced one of the complications, ... In this trial, 0.5 percent of Lovenox patients experienced bleeding, ... Bloomberg DJ MARKET TALK: Sanofi Lovenox Alternative Not Good News - Aug 23, 2006 1252 GMT [Dow Jones] The better, cheaper alternative to Sanofi-Aventis's (SNY) Lovenox, as highlighted in a study published in a US medical journal, ... newratings.com STOCKWATCH Sanofi edges down on concerns over drugs pipeline, … - Sep 21, 2007 In their view, the Acomplia issue, combined with uncertainties over Lovenox, is likely to lead to an underperformance in Sanofi shares relative to the ... Forbes Sanofi Takes Patent Hit - Feb 8, 2007 In June 2005, a federal judge granted the challengers summary judgment in a dispute over two Lovenox patents. In April 2006, a federal appeals court ... TheStreet.com - TheStreet.com (subscription) Q3 2005 Momenta Earnings Conference Call - Final. - Nov 2, 2005 M-Enoxaparin is our generic version of Lovenox, an anti-coagulant drug used in ... Lovenox is a naturally derived drug that consists of a complex mixture of ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Boehringer Cleared to Sell Pradaxa, Beating Bayer - Mar 27, 2008 Clinical tests showed Pradaxa to have similar benefits to Lovenox, ... Lovenox is a version of naturally occurring heparin, which is derived from pig ... Bloomberg Sanofi lifts year outlook despite lower Q1 profits - May 3, 2007 Its sleeping pill Ambien lost US patent protection last month and generic versions of anti-clotting drug Lovenox could also soon be approved, ... Reuters STOCKS NEWS EUROPE-Sanofi jumps after Morgan Stanley upgrade - Nov 24, 2008 ...two sources of near-term upside -- further near-term cost reduction and potential delays to generic versions of Sanofi's top-sellers Lovenox and Plavix. Reuters UK Oral Drug Helps Prevent Clotting After Hip Replacement - Jun 25, 2008 Current guidelines recommend patients receive a heparin-based preventive drug such as enoxaparin (Lovenox) for a minimum of 10 days, and up to 35 days, ... Washington Post Paris shares up at midday; Alcatel-Lucent leads - Feb 9, 2007 The other major focus of the morning was Sanofi-Aventis, which fell 1.30 or 1.92 pct to 66.50 after it lost its US lawsuit to protect blockbuster Lovenox ... ABCmoney.co.uk … Prophylaxis With Clexane(R) / Lovenox(R) (enoxaparin Sodium... - Jul 8, 2007 Lovenox(R) is a unique chemical entity in a class of antithrombotic agents ... 1 selling low-molecular weight heparin in the world, Lovenox(R) is obtained ... ots.at … Medicare Part D drive; Sanofi-Aventis Lovenox patent questioned;... - Jun 16, 2005 Shares in Sanofi-Aventis fell 5 percent after a US court invalidated the patent for its blood thinner Lovenox. Story. > California considers giving the ... FierceHealthcare Neupro, Lovenox.(New & Approved) - Aug 1, 2007 A transdermal patch containing rotigotine, a nonergotamine dopamine agonist, for treating the signs and symptoms of early-stage idiopathic Parkinson's ... Free with registration - Skin & Allergy News - AccessMyLibrary.com FDA Approves Lovenox® (Enoxaparin Sodium Injection) For The Most … - May 20, 2007 Sanofi-aventis announced today that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the anticoagulant ... Medical News Today - Medical News Today (press release) New Data Reveals That Enoxaparin Results In Significant Cost Savings ... - Jun 21, 2006 Lovenox(R) (enoxaparin sodium injection) is a unique chemical entity in a ... Numerous clinical studies have demonstrated that Lovenox(R) is a safe and ... Medical News Today - Medical News Today (press release) ASA: Lovenox Bests Unfractionated Heparin Versus Post-Stroke … - Feb 12, 2007 By Crystal Phend, Staff Writer, MedPage Today. SAN FRANCISCO, Feb. 12 -- The low molecular weight heparin Lovenox (enoxaparin) reduces the relative risk of ... MedPage Today Sanofi Study Shows Extended Lovenox Regimen Reduces VTE Risk - Jul 9, 2007 Sanofi-Aventis says extending prophylaxis with its Clexane/Lovenox injection to five weeks is more effective than 10 days for reducing the risk of venous ... RedOrbit FDA priority review for Sanofi's Lovenox in STEMI. - Feb 12, 2007 FDA priority review for Sanofi's Lovenox in STEMI. The Food and Drug Administration has accepted for review a supplemental New Drug Application for ... $9.94 - Pharma Marketletter - Alacra Store Prophylactic Lovenox cuts VTE risk 44%.(venous thromboembolism )( … - Jul 16, 2007 Leading French drugmaker Sanofi-Aventis says that the results of the EXCLAIM study indicate the significant therapeutic benefits that prophylactic treatment ... Free with registration - Pharma Marketletter - AccessMyLibrary.com ASH: Lovenox Prevails Against Venous Thromboembolism in Ischemic … - Dec 15, 2006 By Neil Osterweil, Senior Associate Editor, MedPage Today. ORLANDO, Dec. 15 -- In patients with acute ischemic stroke, daily Lovenox (enoxaparin) was ... MedPage Today => New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term … - Mar 9, 2007 Paris (ots/PRNewswire) - Sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net ... FinanzNachrichten.de Article: Neupro, Lovenox.(New & Approved)(Medical condition overview)... - Jul 1, 2007 Neupro, Lovenox.(New & Approved)(Medical condition overview) ... find Family Practice News articles. Neupro (Rotigotine Transdermal System, Schwarz Pharma) ... Pay-Per-View - Family Practice News - HighBeam Research Sanofi-Aventis gets non-approvable letter from US FDA for Dronedarone. - Aug 31, 2006 Separately, Sanofi said a trial associated with a challenge on the patent of its blockbuster Lovenox anticoagulant, brought against Amphastar and Teva, ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Sanofi-Aventis loses US Lovenox patent case. - Feb 19, 2007 Sanofi-Aventis loses US Lovenox patent case. French pharmaceutical major Sanofi-Aventis saw its share price come under pressure on February 9, ... $9.94 - Pharma Marketletter - Alacra Store Press Release: Lovenox(R) Patent Trial Update. - PR Newswire | … - Jun 16, 2005 Lovenox(R) Patent Trial Update. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … (R) Significantly Reduced Major Bleeding Compared to LOVENOX(R) in... - Apr 6, 2006 Headline Results: ARIXTRA was as effective as LOVENOX for the primary composite endpoint of preventing death, myocardial infarction, and refractory ischemia ... Free with registration - PR Newswire - AccessMyLibrary.com Fortune 40: Stock picks to retire on - Sanofi-Aventis (37) - FORTUNE - Jun 11, 2007 Stroke drug Lovenox is its top seller, and sales are rapidly growing for its insulin brand Lantus. The French pharma giant has managed to grow the franchise ... CNNMoney.com Momenta's Trials May Continue As FDA Slows Generic Lovenox - Nov 12, 2007 By Randall Osborne. The FDA's stance on generics - at least on versions of the blood thinner Lovenox, such as Momenta Pharmaceuticals Inc.'s M-Enoxaparin ... BioWorld Online - BioWorld Online Getting Used to Lovenox - Jan 29, 2007 I've grown a new appreciation for people who have to give themselves shots on a daily basis. Yes, I mean shots with needles. Many of those people include ... HealthCentral.com Press Release: Clexane(R)/Lovenox(R) Approved in Japan. - PR … - Jan 28, 2008 Clexane(R)/Lovenox(R) Approved in Japan. from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: Clexane(R)/Lovenox(R) Approved in Japan. - PR … - Jan 28, 2008 Clexane(R)/Lovenox(R) Approved in Japan. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Problems for Sanofi on Lovenox ruling.(Sanofi-Aventis SA)(Brief... - Jun 27, 2005 The Paris bourse registered a thumbs-down for Sanofi-Aventis following the decision of the US tribunal on the Lovenox (enoxaparin) patent. ... $4.95 - Pharma Marketletter - ECNext Sanofi-aventis (SNY) Said New Lovenox Trial Set for Dec 4 - Aug 31, 2006 Sanofi-aventis (NYSE: SNY) announced today that the US District Court for the Central District of California has set a revised trial date of December 4, ... StreetInsider.com - StreetInsider.com (subscription) Sanofis Lovenox Works Better Than UFH In Strokes. - Dec 13, 2006 December 13, 2006 (FinancialWire) Sanofi-Aventis SA (NYSE: SNY) bloodthinner Lovenox, or enoxaparin, works better than another types of anti-thrombosis ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Sanofi Dealt Another Blow in Lovenox Case - May 22, 2008 A federal court has upheld a ruling that patents covering sanofi-aventis' blood thinner Lovenox are unenforceable due to inequitable conduct. ... FDA news - FDA news (subscription) US Federal Appeals Court: Teva can't sell Lovenox. | Article from... - Apr 11, 2006 US Federal Appeals Court: Teva can't sell Lovenox. ... find Globes (Tel Aviv, Israel) articles. Byline: Yuval Mendelson Apr. 11--Teva Pharmaceutical ... Pay-Per-View - Globes - HighBeam Research FDA Grants Priority Review to Lovenox(R) (Enoxaparin Sodium Injection)... - Feb 7, 2007 BRIDGEWATER, NJ, Feb. 7 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today the Food and Drug Administration (FDA) has accepted for review a ... RedOrbit Study Shows That Low-Molecular Weight Heparin (LMWH) was … - Dec 10, 2007 Lovenox was associated with reduced cost in most categories although ... For every 1000 patients treated for documented DVT, the use of Lovenox may save ... Free with registration - PR Newswire - AccessMyLibrary.com Blood Thinner Lovenox Recalled Over Contamination Concerns - May 18, 2008 French health authorities have just ordered the recall of 11 batches of Sanofi-Aventis' anti-clotting drug Lovenox. The withdrawal is taking place as a ... Newsinferno.com No Clinical Trials Required for Sandoz' Generic Lovenox - May 9, 2008 The FDA will not require human clinical trials to support the ANDA for Sandoz and Momenta's generic version of the anticoagulant Lovenox, which previously ... FDA news - FDA news (subscription) Sanofi sues Novartis in US over generic challenge to Lovenox. - Aug 9, 2006 Citigroup analysts recently warned a European challenge to Lovenox by Novartis could knock as much as 7 eur off Sanofi's valuation, if launched in mid-2007 ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Sanofi-Aventis wins Lovenox patent appeal.(against Amphastar … - Apr 17, 2006 French drug major Sanofi-Aventis says that the US Federal Court has ruled in its favor regarding a patent infringement suit it had filed against Amphastar ... Free with registration - Pharma Marketletter - AccessMyLibrary.com USPTO approves Sanofi-Aventis Lovenox patent renewal.(Brief Article) - Jan 3, 2005 Sanofi-Aventis has received approval from the US Patents and Trademark Office for its request for a renewal of the patent on its major anti-thrombosis drug ... $4.95 - Pharma Marketletter - ECNext Article: Teva wins Lovenox patent case: A US District Court in... - Feb 11, 2007 Teva wins Lovenox patent case: A US District Court in California cancelled Sanofi-Aventis's patent to Lovenox, which was originally due to expire in 2012. Pay-Per-View - Globes - HighBeam Research Superior Safety Profile Of LOVENOX(r) Vs. Unfractionated Heparin... - Sep 9, 2006 The New England Journal of Medicine publishes the international STEEPLE trial (Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention ... Medical News Today - Medical News Today (press release) Bristol, Sanofi fighting Apotex over blockbuster rights - Aug. 18,... - Aug 18, 2006 Lovenox is similar to biotech drugs in its difficulty and complexity to manufacture, ... Roy said that loss of Lovenox could be particularly dangerous to ... CNNMoney.com … : New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term … - Sep 2, 2007 New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome.(Clinical report) from PR ... Pay-Per-View - PR Newswire Europe - HighBeam Research … : New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term … - Sep 2, 2007 New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Article: Lovenox.(NEW & APPROVED) - Internal Medicine News | … - Jul 1, 2007 Lovenox.(NEW & APPROVED) ... find Internal Medicine News articles. Lovenox (enoxaparin, Sanofi-Aventis) A low-molecular-weight heparin approved for treat... Pay-Per-View - Internal Medicine News - HighBeam Research Sanofi-Aventis Announces Positive Trial Data for Taxotere, Lovenox - Sep 12, 2007 Individual patient data from seven clinical trials showed that sanofi-aventis' Taxotere had a significant overall survival benefit in treating patients with ... FDA news - FDA news (subscription) Brand Names/Synonyms: Lovenox is also known by the following brand names and/or synonymsEnoxaparin; Enoxaparin Sodium; Heparin; Heparin Sodium; Heparin Sodium Salt; Lovenox; Lovenox Hp; Low Molecular Weight Heparin Sodium Drug Category: Lovenox is categorized under the following by the FDA: Fibrinolytic Agents; Anticoagulants; Heparins; ATC:B01AB05 Dosage Forms: Solution for subcutaneous injection Absorption: ~100% following subcutaneous injection Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 6-[5-acetylamino-4,6-dihydroxy-2-(sulfooxymethyl)tetrahydropyran-3-yl]oxy-3-[5-(6-carboxy-4,5-dihydroxy-3-sulfooxy-tetrahydropyran-2-yl)oxy-6-(hydroxymethyl)-3-sulfoamino-4-sulfooxy-tetrahydropyran-2-yl]oxy-4-hydroxy-5-sulfooxy-tetrahydropyran-2-carboxylicacid |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |